GlassScriptPhysician profile
Uticia Belfield
NPI 1235369042
$8,199.51
in general payments reported to CMS, 2019-2025
33 companies · $1,030 in 2025
The $1,030 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $708 · 2021: $1,146 · 2022: $1,194 · 2023: $2,099 · 2024: $1,354 · 2025: $1,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,483.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,580.98 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $855.05 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $575.89 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $557.98 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $535.73 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $524.80 | 2019-2025 | |
| Lilly USA, LLC | $517.25 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $421.21 | 2021-2025 | Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $332.71 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $331.80 | 2019-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $329.15 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $284.69 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $224.78 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $173.74 | 2023-2025 | Auvelity |
| Astellas Pharma US INC | $148.99 | 2020-2025 | Veozah |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $143.74 | 2019-2024 | Freestyle Libre |
| Novartis Pharmaceuticals Corporation | $76.04 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $75.40 | 2024 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $63.31 | 2021 | |
| Amarin Pharma, INC. | $61.72 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $57.05 | 2022 | |
| Antares Pharma, INC. | $48.08 | 2024 | Xyosted |
| Merck Sharp & Dohme LLC | $46.62 | 2020-2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Biohaven Pharmaceutical Holding Company LTD. | $40.61 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $40.46 | 2019-2021 | |
| Teleflex LLC | $30.64 | 2023 | Urolift |
| Medtronic, INC. | $29.85 | 2025 | Minimed 780g |
| Amgen INC. | $19.89 | 2025 | Repatha, Otezla |
| Supernus Pharmaceuticals, INC. | $17.45 | 2019 | |
| Endo Pharmaceuticals INC. | $17.23 | 2020 | |
| Currax Pharmaceuticals LLC | $13.85 | 2021 | |
| Horizon Therapeutics Plc | $11.95 | 2020 | |
| Allergan, INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uticia Belfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.